Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer.
The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multiparametric Prostate MRI | Diagnostic Test | Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lesion location | Both MRI and PET results will be compared. Lesion location will be defined as "left", "right", "apical", "basal", "midline". | Between prostate biopsy and curative treatment decision , usually 2 month |
| Lesion Size | Both MRI and PET results will be compared, Lesion size will be stated in milimeters. | Between prostate biopsy and curative treatment decision , usually 2 month |
| Lymph node involvement | Both MRI and PET results will be compared. Involvement will be stated as "exist", "non-exist". | Between prostate biopsy and curative treatment decision , usually 2 month |
| Extraprostatic involvement | Both MRI and PET results will be compared. Involvement will be stated as "exist" , "non-exist". | Between prostate biopsy and curative treatment decision , usually 2 month |
| Local and distant metastasis | Both MRI and PET results will be compared. Metastasis will be stated as "exist" , "non-exist". | Between prostate biopsy and curative treatment decision , usually 2 month |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Because of prostate cancer study
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Can Sicimli, M.D. | Contact | +905077287879 | cansicimli@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gulhane Research and Training Hospital | Recruiting | Ankara | Etlik | 06010 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
47 male patients who will be evaluated with both imaging studies will be included in the study.
Not provided
Not provided
Not provided
Not provided
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |